These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 29550516)

  • 1. Improved immune response against HIV-1 Env antigen by enhancing EEV production via a K151E mutation in the A34R gene of replication-competent vaccinia virus Tiantan.
    Yu J; Li Y; Zhong M; Yang J; Zhou D; Zhao B; Cao Y; Yan H; Zhang E; Yang Y; Feng Z; Qi X; Yan H
    Antiviral Res; 2018 May; 153():49-59. PubMed ID: 29550516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 vaccines based on replication-competent Tiantan vaccinia protected Chinese rhesus macaques from simian HIV infection.
    Liu Q; Li Y; Luo Z; Yang G; Liu Y; Liu Y; Sun M; Dai J; Li Q; Qin C; Shao Y
    AIDS; 2015 Mar; 29(6):649-58. PubMed ID: 25849828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucosal Immunization with Newcastle Disease Virus Vector Coexpressing HIV-1 Env and Gag Proteins Elicits Potent Serum, Mucosal, and Cellular Immune Responses That Protect against Vaccinia Virus Env and Gag Challenges.
    Khattar SK; Manoharan V; Bhattarai B; LaBranche CC; Montefiori DC; Samal SK
    mBio; 2015 Jul; 6(4):e01005. PubMed ID: 26199332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccinia virus glycoprotein A34R is required for infectivity of extracellular enveloped virus.
    McIntosh AA; Smith GL
    J Virol; 1996 Jan; 70(1):272-81. PubMed ID: 8523536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2017 May; 91(9):. PubMed ID: 28179536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UV-inactivated vaccinia virus (VV) in a multi-envelope DNA-VV-protein (DVP) HIV-1 vaccine protects macaques from lethal challenge with heterologous SHIV.
    Jones BG; Sealy RE; Zhan X; Freiden PJ; Surman SL; Blanchard JL; Hurwitz JL
    Vaccine; 2012 May; 30(21):3188-95. PubMed ID: 22425790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Env-2dCD4 S60C complexes act as super immunogens and elicit potent, broadly neutralizing antibodies against clinically relevant human immunodeficiency virus type 1 (HIV-1).
    Killick MA; Grant ML; Cerutti NM; Capovilla A; Papathanasopoulos MA
    Vaccine; 2015 Nov; 33(46):6298-306. PubMed ID: 26432912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes.
    Gherardi MM; Nájera JL; Pérez-Jiménez E; Guerra S; García-Sastre A; Esteban M
    J Virol; 2003 Jun; 77(12):7048-57. PubMed ID: 12768024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations.
    Andersson AC; Ragonnaud E; Seaton KE; Sawant S; Folgori A; Colloca S; Labranche C; Montefiori DC; Tomaras GD; Holst PJ
    Vaccine; 2016 Oct; 34(44):5344-5351. PubMed ID: 27633665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A human immunodeficiency virus type 1 Env-granulocyte-macrophage colony-stimulating factor fusion protein enhances the cellular immune response to Env in a vaccinia virus-based vaccine.
    Rodr Guez D; Rodr Guez JR; Llorente M; V Zquez I; Lucas P; Esteban M; Mart Nez-A C; Del Real G
    J Gen Virol; 1999 Jan; 80 ( Pt 1)():217-223. PubMed ID: 9934705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC.
    Kibler KV; Asbach B; Perdiguero B; García-Arriaza J; Yates NL; Parks R; Stanfield-Oakley S; Ferrari G; Montefiori DC; Tomaras GD; Roederer M; Foulds KE; Forthal DN; Seaman MS; Self S; Gottardo R; Phogat S; Tartaglia J; Barnett S; Cristillo AD; Weiss D; Galmin L; Ding S; Heeney JL; Esteban M; Wagner R; Pantaleo G; Jacobs BL
    J Virol; 2019 Feb; 93(3):. PubMed ID: 30429340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissociation of progeny vaccinia virus from the cell membrane is regulated by a viral envelope glycoprotein: effect of a point mutation in the lectin homology domain of the A34R gene.
    Blasco R; Sisler JR; Moss B
    J Virol; 1993 Jun; 67(6):3319-25. PubMed ID: 8497053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeras between the human immunodeficiency virus (HIV-1) Env and vaccinia virus immunogenic proteins p14 and p39 generate in mice broadly reactive antibodies and specific activation of CD8+ T cell responses to Env.
    Collado M; Rodríguez D; Rodríguez JR; Vázquez I; Gonzalo RM; Esteban M
    Vaccine; 2000 Jul; 18(27):3123-33. PubMed ID: 10856792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of humoral, mucosal, and cellular immune responses following co-immunization of HIV-1 Gag and Env proteins expressed by Newcastle disease virus.
    Khattar SK; Palaniyandi S; Samal S; LaBranche CC; Montefiori DC; Zhu X; Samal SK
    Hum Vaccin Immunother; 2015; 11(2):504-15. PubMed ID: 25695657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.
    Townsley S; Mohamed Z; Guo W; McKenna J; Cleveland B; LaBranche C; Beaumont D; Shen X; Yates NL; Pinter A; Tomaras GD; Ferrari G; Montefiori DC; Hu SL
    J Virol; 2016 Oct; 90(19):8644-60. PubMed ID: 27440894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenicity and immunogenicity of recombinant Tiantan Vaccinia Virus with deleted C12L and A53R genes.
    Dai K; Liu Y; Liu M; Xu J; Huang W; Huang X; Liu L; Wan Y; Hao Y; Shao Y
    Vaccine; 2008 Sep; 26(39):5062-71. PubMed ID: 18573290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens.
    Galmiche MC; Goenaga J; Wittek R; Rindisbacher L
    Virology; 1999 Feb; 254(1):71-80. PubMed ID: 9927575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The improved antibody response against HIV-1 after a vaccination based on intrastructural help is complemented by functional CD8+ T cell responses.
    Storcksdieck genannt Bonsmann M; Niezold T; Hannaman D; Überla K; Tenbusch M
    Vaccine; 2016 Apr; 34(15):1744-51. PubMed ID: 26945099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eliciting HIV-1 envelope-specific antibodies with mixed vaccinia virus recombinants.
    Rencher SD; Lockey TD; Srinivas RV; Owens RJ; Hurwitz JL
    Vaccine; 1997 Feb; 15(3):265-72. PubMed ID: 9139484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA prime/MVTT boost regimen with HIV-1 mosaic Gag enhances the potency of antigen-specific immune responses.
    Liu W; Wong YC; Chen SMY; Tang J; Wang H; Cheung AKL; Chen Z
    Vaccine; 2018 Jul; 36(31):4621-4632. PubMed ID: 29961605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.